MedTrace Logo

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

NCT00000950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-03-02

No results posted yet for this study

Summary

The purpose of this study is to determine if a relationship exists between the level of antituberculosis drugs (isoniazid, rifampin, ethambutol, and pyrazinamide) in the blood and the outcome of HIV-positive patients with tuberculosis. This study also evaluates how these drugs are absorbed and metabolized in the body.

Conditions

Interventions

DRUG

Ethambutol hydrochloride

DRUG

Isoniazid

DRUG

Pyrazinamide

DRUG

Pyridoxine hydrochloride

DRUG

Rifampin

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Keith Chirgwin

  • David Perlman

Study Design

Purpose
TREATMENT

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2002-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000950 on ClinicalTrials.gov